Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Trial of CV7201 Rabies Vaccine
NCT02241135Phase 1Completed
- Sponsor
- CureVac
- Start
- Oct 2013
- Primary completion
- Feb 2018
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of nadorameran in rabies (8 arms), sponsored by CureVac. Primary endpoint: Incidence and severity of serious adverse events (SAEs)/adverse events (AEs) and local tolerability assessment. Started Oct 2013; status: completed.
02
Drugs
nadorameran
03
Conditions
rabies
Beyond the preview
Go deeper on NCT02241135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241135.